US biotech company Dyadic Applied BioSolutions has announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European company for additional precision-fermented dairy proteins.

Dyadic, based in Florida, develops recombinant protein solutions across the life sciences, food and nutrition, bioindustrial and biopharmaceutical markets.

Its latest announcement marks the growth of its food and nutrition pipeline, aligning with its strategy of developing recurring revenue opportunities through strategic development partnerships, licensing and commercial participation.

The new programme builds on Dyadic’s growing portfolio of non-dairy proteins and enzymes, including the commercial launch of recombinant bovine chymosin through Denmark-based company Inzymes and the ongoing development of recombinant bovine alpha-lactalbumin with Dutch group Brig Bio.

The programmes showcase how Dyadic’s Dapibus precision fermentation platform can repeatedly generate dairy proteins and enzymes that can serve multiple food and nutrition markets.

Dapibus is designed to rapidly develop and manufacture recombinant food proteins and enzymes using established microbial fermentation processes and existing industrial fermentation infrastructure, aiming to support efficient, scalable and cost-effective production.

Under the agreement, Dyadic is eligible to receive development and commercial payments, licensing-related revenues and other potential economic participation tied to successful commercialisation, creating multiple pathways for future revenue generation.

Amid growing demand for high-quality animal-free dairy ingredients, the proteins being developed are intended for a wide range of applications supporting improved functionality, texture and nutritional performance.

The programme will now advance through strain optimisation, process development and commercial scale-up activities as Dyadic continues expanding its food and nutrition portfolio with strategic partners.

Joe Hazelton, president and chief operating officer of Dyadic Applied BioSolutions, said: “Together with the commercialisation of recombinant bovine chymosin through our partnership with Inzymes and our ongoing bovine alpha-lactalbumin collaboration with Brig Bio, we are building a diversified pipeline of precision-fermented dairy proteins and enzymes”.

“Each new programme further strengthens the Dapibus platform as a repeatable engine for commercial growth.”